ropivacaine sustained release (GB-6002)
/ G2GBIO
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 18, 2024
Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults
(clinicaltrials.gov)
- P1 | N=40 | Completed | Sponsor: G2GBio, Inc. | Recruiting ➔ Completed | N=30 ➔ 40 | Trial completion date: Mar 2024 ➔ Sep 2024 | Trial primary completion date: Mar 2024 ➔ Sep 2024
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Pain
October 23, 2023
Dose-Escalation, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GB-6002 Local Infiltration in Healthy Male Adults
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: G2GBio, Inc.
New P1 trial • Pain
1 to 2
Of
2
Go to page
1